• Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)
  • Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)
  • Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)
  • Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)
  • Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)
  • Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)

Human LFA-3/CD58 protein (Recombinant) (C-hFc&His) (STJP001027)

SKU:
STJP001027

Current Stock:
Host: HEK293 cells
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human LFA-3/CD58-C-hFc&His protein was developed from hek293 cells and has a target region of C-hFc&His. For use in research applications.
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.
Immunoreactivity: Measured by its binding ability in a functional ELISA. Immobilized Human CD2 at 2 Mu g/mL (100 Mu L/well) can bind Human CD58 with a linear range of 1.22-34.4 ng/mL.2. Measured by its binding ability in a functional ELISA. Immobilized CD58 (LFA-3) Mo
Gene Symbol: CD58
Gene ID: 965
Uniprot ID: LFA3_HUMAN
Immunogen: Recombinant Human LFA-3/CD58 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Phe 29-Arg 215 ) of human CD58 (Accession #BC005930) fused with an Fc, 6Ă—His tag at the C-terminus.
Protein Name Lymphocyte Function-Associated Antigen 3
Ag3
Surface Glycoprotein Lfa-3
Cd Antigen Cd58
Database Links Reactome: R-HSA-202733
Reactome: R-HSA-6798695
Cellular Localisation Isoform 1: Cell Membrane
Single-Pass Type I Membrane Protein
Alternative Protein Names Lymphocyte Function-Associated Antigen 3 protein
Ag3 protein
Surface Glycoprotein Lfa-3 protein
Cd Antigen Cd58 protein
CD58 protein
LFA3 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance